Lakefront Biotherapeutics NV
LKFT
$27.22
-$0.21-0.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 85.87% | -99.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 85.87% | -99.29% | |||
| Cost of Revenue | -3.56% | -67.35% | |||
| Gross Profit | 23.36% | -103.64% | |||
| SG&A Expenses | -36.95% | 8.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -42.77% | 96.68% | |||
| Total Operating Expenses | -21.17% | -36.02% | |||
| Operating Income | 32.06% | -107.92% | |||
| Income Before Tax | -85.64% | -98.24% | |||
| Income Tax Expenses | -0.50% | -89.64% | |||
| Earnings from Continuing Operations | -86.07% | -98.25% | |||
| Earnings from Discontinued Operations | -72.91% | 274.15% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.52% | -98.17% | |||
| EBIT | 32.06% | -107.92% | |||
| EBITDA | 24.71% | -106.83% | |||
| EPS Basic | -85.54% | -98.17% | |||
| Normalized Basic EPS | 43.69% | -103.07% | |||
| EPS Diluted | -85.58% | -98.17% | |||
| Normalized Diluted EPS | 43.83% | -103.07% | |||
| Average Basic Shares Outstanding | 0.04% | -0.05% | |||
| Average Diluted Shares Outstanding | 0.25% | -0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||